VX-702

For research use only. Not for use in humans.

目录号:S6005

VX-702 Chemical Structure

CAS No. 745833-23-2

VX-702是一种高选择性p38α MAPK抑制剂,作用于p38α比作用于p38β效果高14倍。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 647.01 现货
RMB 575.24 现货
RMB 3023.34 现货
RMB 5477.38 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的VX-702发表文献32篇:

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

产品描述 VX-702是一种高选择性p38α MAPK抑制剂,作用于p38α比作用于p38β效果高14倍。Phase 2。
特性 VX-702是高选择性,口服有效的p38 MAPK 抑制剂。
靶点
p38α [1]
(Cell-free assay)
4 nM-20 nM
体外研究

用1 μM VX-702处理血小板,完全或局部抑制由血小板兴奋剂(包括凝血酵素, SFLLRN, AYPGKF, U46619, 和胶原)诱导的p38活性,IC50为4到20 nM。VX-702作用于p38 MAPK兴奋剂诱导的血小板聚集没有效果。[1]VX-702 抑制IL-6, IL-1β和TNFα 的产生,IC50分别为59, 122和99 ng/ml,这种作用存在剂量依赖性。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoP4TY5pcWKrdHnvckBw\iCqdX3hckBJV1BvNkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlAyPTR|IN88US=> M4\MfXNCVkeHUh?=
human NCI-H720 cell NUfsWm1TT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUj3S2pMUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFczOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMEG2PFIh|ryP MlSxV2FPT0WU
JVM-2 cell NVTHWIl5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXnPSIxzUW6qaXLpeIlwdiCxZjDoeY1idiCMVl2tNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh|IN88US=> MnvUV2FPT0WU
human NCI-H69 cell M4fse2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1fy[WlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODl7NEGg{txO NFrJdJRUSU6JRWK=
human BV-173 cell M{TBVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYHJcohq[mm2aX;uJI9nKGi3bXHuJGJXNTF5MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVE{QDZizszN M4j3Z3NCVkeHUh?=
human KU812 cell NV;5OGRlT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmjFTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVI1QDhizszN MkLlV2FPT0WU
human DU-145 cell M13DTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPl[|ZPUW6qaXLpeIlwdiCxZjDoeY1idiCGVT2xOFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF2NUW0JO69VQ>? NFHtV2ZUSU6JRWK=
KARPAS-45 cell M4LQ[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHvwO21KdmirYnn0bY9vKG:oIHj1cYFvKEuDUmDBV{01PSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUS4NlYh|ryP NYnsd|lxW0GQR1XS
human AGS cell MkDES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{\N[GlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOVI2OSEQvF2= MmHhV2FPT0WU
human MOLT-13 cell NWGwPItrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFr1PGhKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3OUixJO69VQ>? M1q0SnNCVkeHUh?=
human NCI-H209 cell MoroS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVfaNYVKUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUe1PEDPxE1? M2nLNHNCVkeHUh?=
human CTV-1 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGDsO5BKdmirYnn0bY9vKG:oIHj1cYFvKEOWVj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQDN6OTFOwG0> NF;MbIJUSU6JRWK=
LU-139 cell MnLMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1vPNWlvcGmkaYTpc44hd2ZiaIXtZY4hVFVvMUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yQTR|NTFOwG0> NGPsWolUSU6JRWK=
ML-2 cell NWDjWnl2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWnJcohq[mm2aX;uJI9nKGi3bXHuJG1NNTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkKyOlYyKM7:TR?= NUPs[G83W0GQR1XS
human K5 cell NIDGT2lIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYjJcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{MkmxO{DPxE1? NYP4OJhGW0GQR1XS
human SBC-1 cell NV24bYw2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV\Me41KUW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN4MjFOwG0> NGDyb3dUSU6JRWK=
human COR-L88 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUnJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OOEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{PDhizszN NXvpeGc6W0GQR1XS
human KY821 cell NYX6eFZ2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFT1VYZKdmirYnn0bY9vKG:oIHj1cYFvKEu\OEKxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTZyMzFOwG0> M3X2[nNCVkeHUh?=
human HCC2218 cell M2PpbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlnQTY5pcWKrdHnvckBw\iCqdX3hckBJS0N{MkG4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41QTd{ODFOwG0> MoHaV2FPT0WU
human ECC10 cell Mm\0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIHlV2tKdmirYnn0bY9vKG:oIHj1cYFvKEWFQ{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PTN6OTFOwG0> MnO4V2FPT0WU
human EW-3 cell M1z5Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYHZOIxlUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PjZzMTFOwG0> M{TF[3NCVkeHUh?=
human EW-18 cell M4DQb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUTUXodPUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2xPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzR4N{mg{txO NUi0d3piW0GQR1XS
human UACC-257 cell NXuzRlN[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlLmTY5pcWKrdHnvckBw\iCqdX3hckBWSUOFLUK1O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjB|Mk[g{txO M2nkUnNCVkeHUh?=
human G-361 cell NF3QOWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkXVTY5pcWKrdHnvckBw\iCqdX3hckBINTN4MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOFk2OTlizszN NVS5VGtKW0GQR1XS
human HMV-II cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MUHJcohq[mm2aX;uJI9nKGi3bXHuJGhOXi2LSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuO|cyQDRizszN MU\TRW5ITVJ?
human DEL cell M1PPUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXjJcohq[mm2aX;uJI9nKGi3bXHuJGRGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwMkC3NFQh|ryP MoHyV2FPT0WU
human IGROV-1 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEO3RmJKdmirYnn0bY9vKG:oIHj1cYFvKEmJUl;WMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjR|MUi4JO69VQ>? MoXtV2FPT0WU
human SK-OV-3 cell M1r5O2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU:YLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlYyPjl5IN88US=> NILHbm1USU6JRWK=
human LAMA-84 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIHiVmZKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjdzMki0JO69VQ>? NIjBdYJUSU6JRWK=
human NCI-H510A cell M1zlNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUPMO2VSUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUyOEFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmyOVI3KM7:TR?= NXK3OZFHW0GQR1XS
human CP66-MEL cell NHzxWIhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{f6XmlvcGmkaYTpc44hd2ZiaIXtZY4hS1B4Nj3NSWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl|NUW5JO69VQ>? Mm\xV2FPT0WU
human HAL-01 cell M1HCcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4G3V2lvcGmkaYTpc44hd2ZiaIXtZY4hUEGOLUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zPzlzODFOwG0> MYDTRW5ITVJ?
human RS4-11 cell  M3LOTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MVfJcohq[mm2aX;uJI9nKGi3bXHuJHJUPC1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuO|A2PzNizszN NWHQSY5NW0GQR1XS
human RPMI-8226 cell MoW5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoLGTY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLUiyNlYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njh{M{e2JO69VQ>? M{LsRXNCVkeHUh?=
human NCI-H82 cell NEDRWFhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUDJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KOEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlg6OzB3IN88US=> MYjTRW5ITVJ?
human NY cells NVvifFZ6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVSyOVBEUW6qaXLpeIlwdiCxZjDoeY1idiCQWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuNlc3OzdizszN M1\LcnNCVkeHUh?=
human MDA-MB-361 cell NIT0OoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUHJcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2zOlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR|MUW4JO69VQ>? MXnTRW5ITVJ?
human MOLT-4 cell NFfhTHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUfJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPVkyQTNizszN M1LxS3NCVkeHUh?=
human DU-4475 cell NELldoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4LRc2lvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODV3NkWg{txO M2flc3NCVkeHUh?=
human ESS-1 cell M1jremdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6yPVE4QSEQvF2= NWLISlNXW0GQR1XS
human NCI-H1299 cell MmrkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFXXRnFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVI6QSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNUOwN|Mh|ryP MWHTRW5ITVJ?
human COLO-684 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1jON2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22PFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjV6MU[1JO69VQ>? NX3DfZh7W0GQR1XS
human MV-4-11 cell Mm\MS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1XGXmlvcGmkaYTpc44hd2ZiaIXtZY4hVVZvND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzFzOUmg{txO MorYV2FPT0WU
human D-542MG cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX3Jcohq[mm2aX;uJI9nKGi3bXHuJGQuPTR{TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlM6Ojd{IN88US=> MUXTRW5ITVJ?
human A4-Fuk cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnzVTY5pcWKrdHnvckBw\iCqdX3hckBCPC2IdXugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ{PjZ{IN88US=> MYXTRW5ITVJ?
human HL-60 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mlr5TY5pcWKrdHnvckBw\iCqdX3hckBJVC14MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOVIzOTJizszN M{\zU3NCVkeHUh?=
human NCI-H526 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{42QThyMTFOwG0> NEPnemtUSU6JRWK=
human L-363 cell NGDtTnZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVTJcohq[mm2aX;uJI9nKGi3bXHuJGwuOzZ|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz63PVI2OiEQvF2= MXrTRW5ITVJ?
human A388 cell MkTkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUGxNHFmUW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45ODN6NDFOwG0> MYLTRW5ITVJ?
human MS-1 MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX3RVI5KUW6qaXLpeIlwdiCxZjDoeY1idiCPUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{45OzR4NTFOwG0> NFnReYdUSU6JRWK=
human JAR cell NH3EOpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MULJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwOES5NlMh|ryP MULTRW5ITVJ?
human TI-73 cell NIXzTYlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkjCTY5pcWKrdHnvckBw\iCqdX3hckBVUS15MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuNFYzOiEQvF2= M4fzR3NCVkeHUh?=
human CTB-1 cell Moi1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1u3eGlvcGmkaYTpc44hd2ZiaIXtZY4hS1SELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlE4QDJ3IN88US=> MlviV2FPT0WU
human SK-NEP-1 cell M{DjbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NW\v[mRyUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OSXAuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFzLkOwN|gh|ryP NUPZcotTW0GQR1XS
human HT-29 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWPJcohq[mm2aX;uJI9nKGi3bXHuJGhVNTJ7IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUOuPVEyOSEQvF2= NF3sOpVUSU6JRWK=
human NCI-H1092 cell M2G0dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVjTfpU{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFExQTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zND6zNVgh|ryP MkWyV2FPT0WU
human KMOE-2 cell NI\rdndIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{jPT2lvcGmkaYTpc44hd2ZiaIXtZY4hU02RRT2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPjF5ODFOwG0> MUfTRW5ITVJ?
human EM-2 cell NUH0WWxyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHzE[WVKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4zQDRzIN88US=> NIi4SGhUSU6JRWK=
human RT-112 cell M4TCUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3HVNWlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvOzl6NDFOwG0> MUnTRW5ITVJ?
human DB cell NUS0NnRqT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGfNWpFKdmirYnn0bY9vKG:oIHj1cYFvKESEIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuPFUyOyEQvF2= NVz4bG5wW0GQR1XS
human NCI-H1770 cell NWi0d29iT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFTlflRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc4OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7 NXXZOo1oW0GQR1XS
human CAL-54 cell NVLT[3oxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4nSUmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzNizszN MofRV2FPT0WU
human NB14 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFHufW9KdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xO{43Ozl3IN88US=> NIf4S4hUSU6JRWK=
human RPMI-7951 cell M{fvZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mnf4TY5pcWKrdHnvckBw\iCqdX3hckBTWE2LLUe5OVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yQS5zN{izJO69VQ>? MXTTRW5ITVJ?
human T47D cell NIfYXGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVfJcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{MT6yNlQ{KM7:TR?= Ml7GV2FPT0WU
human A549 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWi5fIRIUW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvOjhzMTFOwG0> M321c3NCVkeHUh?=
human A2780 cell NVm5SGFIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1PSVmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJ5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU45OjJ3IN88US=> NHvyOJlUSU6JRWK=
human SK-MEL-24 cell NInLdm9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVM{NjB|MUGg{txO MYPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

体内研究 VX-702半衰期为16到20小时,半数清除剂量3.75 L,分布容积为73 L/kg。 [2]VX-702按0.1 mg/kg剂量每天处理两次,与methotrexate 按0.1 mg/kg剂量处理效果差不多。此外,VX-702按5 mg/kg剂量每天处理两次,与prednisolone按10 mg/kg剂量每天处理一次,效果差不多,测定腕关节病变和炎症抑制百分数。[3] VX-702选择性抑制p38 MAPK活性,对ERKs和JNKs没有抑制效果。按50-mg/kg剂量处理的实验组与对照组和按5-mg/kg剂量处理实验组相比,MI/AAR比率明显降低。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

溶解度 (25°C)

体外 DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O
4 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 404.3
化学式

C19H12F4N4O2

CAS号 745833-23-2
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Drug: VX-702 Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

相关p38 MAPK产品

Tags: 购买VX-702 | VX-702供应商 | 采购VX-702 | VX-702价格 | VX-702生产 | 订购VX-702 | VX-702代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID